Featured Publications
Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers
Aguolu OG, Willebrand K, Elharake JA, Qureshi HM, Kiti MC, Liu CY, Mesa A, Nelson K, Jenness S, Melegaro A, Ahmed F, Yildirim I, Malik FA, Lopman B, Omer SB. Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers. Human Vaccines & Immunotherapeutics 2022, 18: 2122379. PMID: 36136345, PMCID: PMC9746537, DOI: 10.1080/21645515.2022.2122379.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationNon-healthcare workersInfluenza vaccinePromotion messagesWorkplace vaccination programsSeasonal influenza vaccinationInfluenza vaccine acceptancePublic health authoritiesLogistic regression modelsInfluenza seasonPhysician recommendationVaccination acceptanceVaccine accessibilityVaccine acceptanceSevere outcomesVaccination programPromotion interventionsUS adultsWork absenceVaccinationVaccination decisionsHealth authoritiesSignificant mortalityUnderstanding predictorsSignificant predictors
2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults
Rostad C, Atmar R, Walter E, Frey S, Meier J, Sherman A, Lai L, Tsong R, Kao C, Raabe V, Sahly H, Keitel W, Whitaker J, Smith M, Schmader K, Swamy G, Abate G, Winokur P, Buchanan W, Cross K, Wegel A, Xu Y, Yildirim I, Kamidani S, Rouphael N, Roberts P, Mulligan M, Anderson E. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clinical Infectious Diseases 2024, 78: 1757-1768. PMID: 38537255, PMCID: PMC11175706, DOI: 10.1093/cid/ciae173.Peer-Reviewed Original ResearchInactivated influenza vaccinePhase 2 clinical trialInfluenza virus vaccineAS03-adjuvantedHemagglutination inhibitionVirus vaccineBoosting intervalsPrime-boost vaccination schedulesHuman influenza A(H7N9Injection site reactogenicityHeterologous prime-boost strategyAntigenically distinct lineagesPrime-boost strategyPrime-boost intervalVaccine groupHealthy US adultsNeutralizing antibody titersPeak antibody responseSystemic reactogenicityInfluenza vaccinePartially-blindedSecond dosePrime-boostReactogenicityImmune response